Entrant HF

Cardiac Resynchronization Therapy Defibrillator (CRT-D)

Entrant HF device next to a phone displaying the myMerlinPulse app

Clinical Evidence

Advanced CRT Optimization

Every patient deserves life-changing therapy. Abbott's next generation CRT-D solutions make it possible for you to achieve clinically meaningful outcomes:

100% of patients had a narrower QRS when SyncAV™ CRT technology was optimized1

  • CRT-induced QRS narrowing has been shown to improve clinical outcomes for heart failure patients2,3


22% fewer heart failure hospitalizations for patients with SyncAV CRT technology enabled vs. patients with the technology disabled4

Manuals & Technical Resources

Customer Service

This device is commercially available for use in select international markets.


  1. Varma N, O’Donnell D, Bassiouny M, et al. Programming cardiac resynchronization therapy for electrical synchrony: reaching beyond left bundle branch block and left ventricular activation delay. J Am Heart Assoc. 2018;7:e007489. https://www.ahajournals.org/doi/10.1161/JAHA.117.007489. Accessed January 14, 2020.
  2. Canadian Cardiovascular Society. Clinical Significance of Electromechanical Dyssynchrony and QRS Narrowing in Patients With Heart Failure Receiving Cardiac Resynchronization Therapy. https://doi.org/10.1016/j.cjca.2018.10.019. Accessed February 25, 2019.
  3. Okafor O, Leyva F, Zegard A, et al. Changes in QRS Area and QRS Duration After Cardiac Resynchronization Therapy Predict Cardiac Mortality, Heart Failure Hospitalizations, and Ventricular Arrhythmias. J Am Heart Assoc. 2019;8:e013539. DOI:10.1161/JAHA.119.013539.
  4. Varma, N., Gain in CRT Efficacy with Dynamic Electrical Optimization: Real World Effect of SyncAV™ CRT on Heart Failure Hospitalizations. Poster presented at EHRA. May 2020. https://esc365.escardio.org/home. Accessed May 15, 2020.

MAT-2009189 v1.0